Dumortier J, et al. - This study represents an attempt to elucidate the antiviral efficacy and safety of sofosbuvir (SOF) in hepatitis C virus (HCV)-infected patients with severe renal failure [including haemodialysis (HD) patients]. Findings strongly suggested that as a treatment option for HCV patients with end-stage renal disease (ESRD), including HD patients, SOF-based antiviral therapy, with a reduced dose of SOF, is safe and effective.